Fluoxetine (Lilly 110140) HCl

Name: Fluoxetine (Lilly 110140) HCl
Brand: Selleck Chemicals
SKU: S1333
Rating: 5 (15 reviews)

For research use only.

Catalog No.S1333

15 publications

Fluoxetine (Lilly 110140) HCl Chemical Structure

CAS No. 56296-78-7

Fluoxetine HCl (Lilly110140) is a selective serotonin-reuptake inhibitor (SSRI) at the neuronal membrane, used in the treatment of depression.

Selleck's Fluoxetine (Lilly 110140) HCl has been cited by 15 publications

FASEB J, 2021, 35(5):e21581

PubMed: 33871072 ( click the link to review the publication )

Sci Rep, 2021, 11(1):1250

PubMed: 33441923 ( click the link to review the publication )

Endocrine, 2021, 10.1007/s12020-021-02818-7

PubMed: 34255273 ( click the link to review the publication )

Biomol Ther (Seoul), 2020, 28(2):202-210

PubMed: 31522488 ( click the link to review the publication )

Radiat Res, 2020, 193(5):407-424

PubMed: 32134362 ( click the link to review the publication )

bioRxiv, 2020, 2020.09.24.312165

PubMed: 32995798 ( click the link to review the publication )

Adv Ther (Weinh), 2020, 2000034

PubMed: 32838027 ( click the link to review the publication )

Expert Opin Ther Targets, 2019, 23(10):883-891

PubMed: 31637934 ( click the link to review the publication )

Anticancer Res, 2019, 39(11):6155-6163

PubMed: 31704843 ( click the link to review the publication )

Neurotherapeutics, 2019, 10.1007/s13311-019-00807-3

PubMed: 31820273 ( click the link to review the publication )

J Neuroinflammation, 2018, 15(1):347

PubMed: 30572907 ( click the link to review the publication )

Brain Res Bull, 2017, 130:146-155

PubMed: 28161195 ( click the link to review the publication )

J Neuroinflammation, 2017, 14(1):186

PubMed: 28903766 ( click the link to review the publication )

G3 (Bethesda), 2014, 4(6):1081-9

PubMed: 24709946 ( click the link to review the publication )

Georgia State University, 2014, Chaquettea Felton

PubMed: ( click the link to review the publication )

3 Customer Reviews

The SWIP phenotype in hlh-17(ns204) animals is unaffected by pretreatment with fluoxetine (C). In all panels, n = 30 animals/rep/strain; dark bars = minus inhibitor; and light bars = plus inhibitor. *P< 0.05; **P<0.005; ***P<0.0005.

G3 (Bethesda), 2014, 4(6):1081-9.. Fluoxetine (Lilly 110140) HCl purchased from Selleck.
Representative photomicrographs of PI-positive neural cells in different groups at 24 h after SAH (n = 3/group). Fluorescence colors: DAPI: blue and PI: red. Scale bar = 100 μm.

J Neuroinflammation, 2017, 14(1):186. Fluoxetine (Lilly 110140) HCl purchased from Selleck.
Immunofluorescence test confirmed the activation of microglia with higher level of TNFα expression. Ipt and Flu treatment clearly reversed the all significant changes to normal levels. White arrows indicate TNFα, CD11b and Hoechst co-located.

Brain Res Bull, 2017, 130:146-155. Fluoxetine (Lilly 110140) HCl purchased from Selleck.

Purity & Quality Control

Choose Selective 5-HT Receptor Inhibitors

Biological Activity

Description

Fluoxetine HCl (Lilly110140) is a selective serotonin-reuptake inhibitor (SSRI) at the neuronal membrane, used in the treatment of depression.

Targets

5-HT ^[1]

In vitro

Fluoxetine blocks the downregulation of cell proliferation resulting from inescapable shock (IS) of hippocampal cell. ^[1] Fluoxetine increases the number of newborn cells in the dentate gyrus of the hippocampus of adult rat. Fluoxetine also increases the number of proliferating cells in the prelimbic cortex. ^[2] Fluoxetine accelerates the maturation of immature neurons. Fluoxetine enhances neurogenesis-dependent long-term potentiation (LTP) in the dentate gyrus. ^[3] Fluoxetine, but not citalopram, fluvoxamine, paroxetine and sertraline, increases norepinephrine and dopamine extracellular levels in prefrontal cortex. Fluoxetine produces robust and sustained increases in extracellular concentrations of norepinephrine and dopamine after acute systemic administration. ^[4]

Cell Data

Cell Lines	Assay Type	Incubation Time	Activity Description	PMID
HEK293	MlT1SpVv[3Srb36gZZN{[Xl?	M2r6ZlMxKG2rboO=	M{LvSGlvcGmkaYTpc44hd2ZiaIXtZY4hW0WUVDDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHHzd4V{e2WmIHHzJIlvcGmkaYTpc44hd2Zic3Xyc5RwdmmwIILleZB1[WunIHHmeIVzKDNyIH3pcpMh[nliZnz1c5Jme2OnbnPlJIF{e2G7LDDJR\|UxRTBwMUZOwG0>	NYnPUpZiRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5N\|gxPDlpPkKyPVM5ODR7PD;hQi=>
HEK293	NY\ZWYFlTnWwY4Tpc44h[XO\|YYm=	MUWzNEBucW6\|	MnTpTY5pcWKrdHnvckBw\iCqdX3hckBPTVRiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjc4Pld5Nm\CCjczDpcohq[mm2aX;uJI9nKG6xcnHkdoVv[WyrbnWgdoV2eHSja3WgZYZ1\XJiM{CgcYlveyCkeTDmcJVwemW\|Y3XuZ4Uh[XO\|YYmsJGlEPTB;ND60Ne69VQ>?	NYLi[nlKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkK5N\|gxPDlpPkKyPVM5ODR7PD;hQi=>
HEK293	MkjZSpVv[3Srb36gZZN{[Xl?	NF7Jeo0{OCCvaX7z	MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGRCXCCneIDy[ZN{\WRiaX6gTGVMOjl\|IHPlcIx{KGG\|c3Xzd4VlKGG\|IHnubIljcXSrb36gc4Yh\G:yYX3pcoUhemW3cIThb4Uh[W[2ZYKgN\|AhdWmwczDifUBndHWxcnXzZ4Vv[2ViYYPzZZktKEmFNUC9NVgvPM7:TR?=	Ml;BQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJ7M{iwOFkoRjJ{OUO4NFQ6RC:jPh?=
mammalian cells	NGDYenhHfW6ldHnvckBie3OjeR?=		NHq4NZlKdmirYnn0bY9vKG:oIHj1cYFvKFCxdHHzd4l2dSClaHHucoVtKEiHUleg[ZhxemW\|c3XkJIlvKG2jbX3hcIlidiClZXzsd{whUUN3ME2xMlUyOzV4zszN	NHjROmk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zMki3N\|UyOid-MUK4O\|M2OTJ:L3G+
JAR	NUH1OYo{TnWwY4Tpc44h[XO\|YYm=		MVHJcohq[mm2aX;uJINwdmOnboTyZZRqd25iYXfhbY5{fCCdM1jdOU1JXCC3cIThb4Uh[nliaIXtZY4he2W{b4TvcolvKHS{YX7zdI9zfGW{IHnuJGpCWiClZXzsd{whUUN3ME2wMlA{OjUQvF2=	MVm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTJ\|OU[2NUc,OTV{M{m2OlE9N2F-
K562	MWnDfZRwfG:6aXPpeJkh[XO\|YYm=		M1LiZ2N6fG:2b4jpZ4l1gSC2bzDy[YR2[2ViY3jyc45q[yCveXXsc4llKGyndXvlcYliKEtiNU[yJINmdGy\|LDDDR\|UxRTJ3zszN	Mn\CQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTV{NkeyNlkoRjF3Mk[3NlI6RC:jPh?=
U937	NVv6UVcyS3m2b4TvfIlkcXS7IHHzd4F6		NXvONGdiS3m2b4TvfIlkcXS7IITvJJJm\HWlZTDoeY1idiCqaYP0c4x6fGmlIHz5cZBpd22jIGW5N\|ch[2WubIOsJGNEPTB;M{OuN:69VQ>?	MVS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPTJ4N{KyPUc,OTV{NkeyNlk9N2F-
HEK293	MVPGeY5kfGmxbjDhd5NigQ>?		M36x[GlvcGmkaYTpc44hd2ZiW{PIYVUuUFRidYD0ZYtmKGG2IEXIWEB1emGwc4DvdpRmeiCneIDy[ZN{\WRiaX6gTGVMOjl\|IHPlcIx{NCCLQ{WwQVAvODF4zszN	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd3MEO1PUc,OTZ5NUCzOVk9N2F-
HEK293	MkfsSpVv[3Srb36gZZN{[Xl?		NIDROo1KdmirYnn0bY9vKG:oIFTBJJRz[W6\|cH;yeIVzKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMtKEmFNUC9OE41\|ryP	M4Xj[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{WwN\|U6Lz5zNke1NFM2QTxxYU6=
HEK293	NILpO\|FHfW6ldHnvckBie3OjeR?=		NWnYR5BPUW6qaXLpeIlwdiCxZjDbN2heVkFidYD0ZYtmKGG2IF7BJJRz[W6\|cH;yeIVzKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMtKEmFNUC9OU4z\|ryP	MVe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPjd3MEO1PUc,OTZ5NUCzOVk9N2F-
HEK293	Mn:5SpVv[3Srb36gZZN{[Xl?		Moq4TY5pcWKrdHnvckBw\iCdM1jdOU1JXCC{ZYXweIFs\SCjdDC1THQhfHKjboPwc5J1\XJiaX6gTGVMOjl\|IHPlcIx{NCCLQ{WwQVAvODF4zszN	M4fjZlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{WwN\|Y{Lz5zNke1NFM3OzxxYU6=
HEK293	MWjGeY5kfGmxbjDhd5NigQ>?		NXPBcGROUW6qaXLpeIlwdiCxZjDbN2heTEFicnX1dJRic2ViYYSgSGEhfHKjboPwc5J1\XJiaX6gTGVMOjl\|IHPlcIx{NCCLQ{WwQVQvPM7:TR?=	M3TtPVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF4N{WwN\|Y{Lz5zNke1NFM3OzxxYU6=
HEK293	Mm\OSpVv[3Srb36gZZN{[Xl?		M{n1cGlvcGmkaYTpc44hd2ZiW{PIYW5CKHKndYD0ZYtmKGG2IF7BJJRz[W6\|cH;yeIVzKGmwIFjFT\|I6OyClZXzsd{whUUN3ME21MlLPxE1?	NIrBW2E9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNke1NFM3Oyd-MU[3OVA{PjN:L3G+
Jar	MVTGeY5kfGmxbjDhd5NigQ>?		NV7aN45TUW6qaXLpeIlwdiCxZjDbN2hePS2KVDD1dJRic2ViYYSgbJVu[W5iNT3IWEB1emGwc4DvdpRmeiCneIDy[ZN{\WRiaX6gToFzKGOnbHzzMEBKSzVyPUCuNFM6PM7:TR?=	NGLSb3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNki1OFA5Pid-MU[4OVQxQDZ:L3G+
SK-N-MC	M3LjUGZ2dmO2aX;uJIF{e2G7		MUjEbZNxdGGlZX3lcpQhd2ZiTj3bN2he[WyyaHGtcYV1cHmuaHnzeIFucW6nIH\yc40hcHWvYX6gbIl{fGGvaX7lJGg{KHKnY3XweI9zKGW6cILld5Nm\CCrbjDTT{1PNU2FIHPlcIx{NCCNaU23MlPPxE1?	MmnRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTd\|MEezOVgoRjF5M{C3N\|U5RC:jPh?=
CHO	MlzLSpVv[3Srb36gZZN{[Xl?		MlLwTY5pcWKrdHnvckBw\iCqdX3hckBGWkdiZYjwdoV{e2WmIHnuJGNJVyClZXzsd{BjgSC5aH;s[UBk\WyuIIDheINpKGOuYX3wJJRm[2iwaYH1[UwhUUN3ME2xMlUyOzV4zszN	NGrNZ\|A9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOES0PFM1Oid-MUi0OFg{PDJ:L3G+
HEK293	NWPHOHI5TnWwY4Tpc44h[XO\|YYm=		NXLRdI5oUW6qaXLpeIlwdiCxZjDz[ZJwfG:waX6geZB1[WunIHH0JIh2dWGwIGPFVnQhcW5iaIXtZY4hUEWNMkmzJINmdGy\|LDDJR\|UxRTBwMES3{txO	NHTDbHY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW1NFM3QSd-MUi1OVA{Pjl:L3G+
HEK293	NVzV[pBjTnWwY4Tpc44h[XO\|YYm=		MVPJcohq[mm2aX;uJI9nKG6xcnXwbY5meGi{aX7lJJVxfGGtZTDheEBpfW2jbjDOSXQhcW5iaIXtZY4hUEWNMkmzJINmdGy\|LDDJR\|UxRTMQvF2=	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDV3MEO2PUc,OTh3NUCzOlk9N2F-
HEK293	MkTFSpVv[3Srb36gZZN{[Xl?		M{TVdGlvcGmkaYTpc44hd2ZiZH;wZY1qdmVidYD0ZYtmKGG2IHj1cYFvKESDVDDpckBpfW2jbjDISWszQTNiY3XscJMtKEmFNUC9Ou69VQ>?	MoD3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh3NUCzOlkoRjF6NUWwN\|Y6RC:jPh?=
JAR	MVXGeY5kfGmxbjDhd5NigQ>?		NV7O[FNmUW6qaXLpeIlwdiCxZjC1THQhfXC2YXvlJIF1KGi3bXHuJHNGWlRiZYjwdoV{e2WmIHnuJIh2dWGwIFrBVkBk\WyuczygTWM2OD1yLkCwPVTPxE1?	NGn0[lQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEW1O\|YxQCd-MUi1OVc3ODh:L3G+
HEK	NGOy[WdHfW6ldHnvckBie3OjeR?=		M4TYTmlvcGmkaYTpc44hd2Zic3Xyc5RwdmmwIIXweIFs\SCjdDDoeY1idiCVRWLUJIV5eHKnc4Pl[EBqdiCKRVugZ4VtdHNuIFnDOVA:OC5yNEhOwG0>	NELaeno9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[2O\|MxQSd-MUi2Olc{ODl:L3G+
HEK	M3XXV2Z2dmO2aX;uJIF{e2G7		M{DtW2lvcGmkaYTpc44hd2Zibn;y[ZBqdmWyaILpcoUhfXC2YXvlJIF1KGi3bXHuJG5GXCCneIDy[ZN{\WRiaX6gTGVMKGOnbHzzMEBKSzVyPUNOwG0>	MmDFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4NkezNFkoRjF6Nk[3N\|A6RC:jPh?=
HEK	NEfoc3BHfW6ldHnvckBie3OjeR?=		NGnUT4ZKdmirYnn0bY9vKG:oIHTvdIFucW6nIIXweIFs\SCjdDDoeY1idiCGQWSg[ZhxemW\|c3XkJIlvKEiHSzDj[YxteyxiSVO1NF03\|ryP	NYDPcm1LRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUi2Olc{ODlpPkG4OlY4OzB7PD;hQi=>
JAR	MYHGeY5kfGmxbjDhd5NigQ>?		M1PDd2lvcGmkaYTpc44hd2Zic3Xyc5RwdmmwIIXweIFs\SCjdDDoeY1idiCVRWLUJIV5eHKnc4Pl[EBqdiCMQWKgZ4VtdHNuIFnDOVA:OC5yMd88US=>	NILoNm49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOEe3NVkyPid-MUi3O\|E6OTZ:L3G+
MDCK	M1zC[mZ2dmO2aX;uJIF{e2G7		NV23O5NNUW6qaXLpeIlwdiCxZjDuc5JmeGmwZYDodolv\SC3cIThb4Uh[XRiaIXtZY4hVkWWIHX4dJJme3OnZDDpckBOTEONIHPlcIx{NCCLQ{WwQVAvPTZ\|zszN	M1r6XFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6N{exPVE3Lz5zOEe3NVkyPjxxYU6=
Jar	M2XlfmZ2dmO2aX;uJIF{e2G7		MkH1TY5pcWKrdHnvckBw\iB3LVjUJJRz[W6\|cH;yeIVzNW2nZHnheIVlKFt\|SG21THQhfXC2YXvlJIlvKGi3bXHuJGpieiClZXzsd{whUUN3ME2wMlA{QTUQvF2=	M1LpfFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6OEO0NVg5Lz5zOEizOFE5QDxxYU6=
JAR	NG\COnRHfW6ldHnvckBie3OjeR?=		NFz6co9KdmirYnn0bY9vKG:oIIPldo91d26rbjD1dJRic2ViYYSgbJVu[W5iU1XSWEBmgHC{ZYPz[YQhcW5iSlHSJINmdGy\|LDDJR\|UxRTBwMEC5OO69VQ>?	MYq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDl3MUCyNEc,OTh7NUGwNlA9N2F-
HEK293	M{nXcWZ2dmO2aX;uJIF{e2G7		MXfEbZNxdGGlZX3lcpQhd2ZiW{GyOWleWlSLNUWg[pJwdSCqdX3hckBz\WOxbXLpcoFvfCCVRWLUJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOsJGtqRTBwMECxNe69VQ>?	M3exb\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MEG0PFg5Lz5zOUCxOFg5QDxxYU6=
HEK293	M{jxd2Z2dmO2aX;uJIF{e2G7		NX;5UIFsUW6qaXLpeIlwdiCxZjDbN2hePUiWIH\yc40hcHWvYX6gdoVkd22kaX7hcpQhW0WUVDDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|LDDJR\|UxRTBwMEC3{txO	NFrPZpU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCxOFg5QCd-MUmwNVQ5QDh:L3G+
HEK293	M3f3T2Z2dmO2aX;uJIF{e2G7		Mn7nTY5pcWKrdHnvckBw\iCdM1jdUmUh\nKxbTDoeY1idiC{ZXPvcYJqdmGwdDDOSXQh\XiycnXzd4VlKGmwIFjFT\|I6OyClZXzsd{whUUN3ME2xMlAz\|ryP	NUHMNHc3RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmwNVQ5QDhpPkG5NFE1QDh6PD;hQi=>
HEK293	NXfxdYJZTnWwY4Tpc44h[XO\|YYm=		MYLEbZNxdGGlZX3lcpQhd2ZiW{GyOWleWlSLNUWg[pJwdSCqdX3hckBz\WOxbXLpcoFvfCCQRWSg[ZhxemW\|c3XkJIlvKEiHS{K5N{Bk\WyuczygT4k:OS53Nt88US=>	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTBzNEi4PEc,OTlyMUS4PFg9N2F-
HEK293	NX[xbopOTnWwY4Tpc44h[XO\|YYm=		MUHEbZNxdGGlZX3lcpQhd2ZiW{GyOWleWlSLNUWg[pJwdSCqdX3hckBz\WOxbXLpcoFvfCCGQWSg[ZhxemW\|c3XkJIlvKEiHS{K5N{Bk\WyuczygT4k:Pi54N988US=>	NGr2VJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCxOFg5QCd-MUmwNVQ5QDh:L3G+
HEK293	MVnGeY5kfGmxbjDhd5NigQ>?		M4H4[2lvcGmkaYTpc44hd2ZiW{PIYWRCKG[{b32gbJVu[W5icnXjc41jcW6jboSgSGFVKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMtKEmFNUC9NVkvPc7:TR?=	NFLQ[3o9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOUCxOFg5QCd-MUmwNVQ5QDh:L3G+
HEK293	NGrhPZFHfW6ldHnvckBie3OjeR?=		MXrEbZNxdGGlZX3lcpQhd2ZiW{GyOWleWlSLLUW1JIZzd21iaIXtZY4hemWlb33ibY5idnRiU1XSWEBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJIJ6KHOlaX70bYxt[XSrb36gZ492dnSrbnesJGtqRTBwMECxNe69VQ>?	M2LCV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkW2OVAzLz5zOUK1OlUxOjxxYU6=
HEK293	M{nOXmZ2dmO2aX;uJIF{e2G7		NF7WVI9FcXOybHHj[Y1mdnRib3[gX\|NJZXOncn;0c45qdiCocn;tJIh2dWGwIILlZ49u[mmwYX70JHNGWlRiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCkeTDzZ4lvfGmubHH0bY9vKGOxdX70bY5oNCCLQ{WwQVAvODB5M988US=>	MXy8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ3NkWwNkc,OTl{NU[1NFI9N2F-
HEK293	NG\Qfo9HfW6ldHnvckBie3OjeR?=		MnjJSIl{eGyjY3Xt[Y51KG:oIGuzTH1vd3KncHnu[ZBpemmwZTDmdo9uKGi3bXHuJJJm[2:vYnnuZY51KE6HVDDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHL5JJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFnDOVA:OS5yMt88US=>	M3vjV\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7MkW2OVAzLz5zOUK1OlUxOjxxYU6=
HEK293	NX3wWoYzTnWwY4Tpc44h[XO\|YYm=		NGTwWmRFcXOybHHj[Y1mdnRib3[gX\|EzPUmfUmTJMVU2KG[{b32gbJVu[W5icnXjc41jcW6jboSgUmVVKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whU2l;MT61Ou69VQ>?	MnL3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTl{NU[1NFIoRjF7MkW2OVAzRC:jPh?=
HEK293	MYXGeY5kfGmxbjDhd5NigQ>?		NF\kPZpFcXOybHHj[Y1mdnRib3[gX\|EzPUmfUmTJMVU2KG[{b32gbJVu[W5icnXjc41jcW6jboSgSGFVKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[nlic3PpcpRqdGyjdHnvckBkd3WwdHnu[{whU2l;Nj62O:69VQ>?	MX28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTJ3NkWwNkc,OTl{NU[1NFI9N2F-
HEK293	NX7KWYNNTnWwY4Tpc44h[XO\|YYm=		NUnHT2VWTGm\|cHzhZ4Vu\W62IH;mJHs{UF2mb4DhcYlv\SCocn;tJIh2dWGwIILlZ49u[mmwYX70JGRCXCCneIDy[ZN{\WRiaX6gTGVMOjl\|IHPlcIx{KGK7IIPjbY51cWyuYYTpc44h[2:3boTpcoctKEmFNUC9NVkvPc7:TR?=	NUTFPIpuRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmyOVY2ODJpPkG5NlU3PTB{PD;hQi=>
JAR	MVzGeY5kfGmxbjDhd5NigQ>?		M4LJTGlvcGmkaYTpc44hd2Zic3Xyc5RwdmmwIIXweIFs\SCjdDDoeY1idiCVRWLUJIV5eHKnc4Pl[EBqdiCqdX3hckBLSVJiY3XscJMtKEmFNUC9NE4xOc7:TR?=	NX7PWIRWRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMUmzNlk{OTNpPkG5N\|I6OzF\|PD;hQi=>
MDCK-Net6	NYL0OoZDTnWwY4Tpc44h[XO\|YYm=		MXnJcohq[mm2aX;uJI9nKG6xcnXwbY5meGi{aX7lJJVxfGGtZTDheEBpfW2jbjDOSXQh\XiycnXzd4VlKGmwIF3ER2suVmW2NjDj[YxteyxiSVO1NF0xNjV4M988US=>	M1rRXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7M{K5N\|E{Lz5zOUOyPVMyOzxxYU6=
JAR	MlHDSpVv[3Srb36gZZN{[Xl?		MW\Jcohq[mm2aX;uJI9nKHOncn;0c45qdiC3cIThb4Uh[XRiaIXtZY4hW0WUVDDlfJBz\XO\|ZXSgbY4hUkGUIHPlcIx{NCCLQ{WwQVAvODB7NN88US=>	M4Dtc\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7NkOyNVExLz5zOU[zNlEyODxxYU6=
JAR	NEjXTphHfW6ldHnvckBie3OjeR?=		MlewTY5pcWKrdHnvckBw\iCqdX3hckBUTVKWIHX4dJJme3OnZDDpckBLSVJiY3XscJMtKEmFNUC9NE4xODl2zszN	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQTdzM{GwOkc,OTl5MUOxNFY9N2F-
JAR	MY\GeY5kfGmxbjDhd5NigQ>?		MYDJcohq[mm2aX;uJI9nKFt\|SG3ofYRzd3i7dIL5dJRidWmwZTDjdoVifGmwaX7lJJN2dG[jdHWgeZB1[WunIHH0JIh2dWGwIGPFVnQh\XiycnXzd4VlKGmwIHj1cYFvKEqDUjDj[YxteyxiSVO1NF0xNjByOUVOwG0>	M2\jTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF7N{KyOVI2Lz5zOUeyNlUzPTxxYU6=
HEK293	M{n1WGZ2dmO2aX;uJIF{e2G7		NXj2R4lUTGm\|cHzhZ4Vu\W62IH;mJHtKOTJ3XWLUTU02PSCocn;tJIh2dWGwIGPFVnQhfHKjboPm[YN1\WRiaX6gbJVu[W5iSFXLNlk{KGOnbHzzMEBKSzVyPUCuNFAzPc7:TR?=	MV[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODB\|NEe5N{c,OjByM{S3PVM9N2F-
JAR	M4S5O2Z2dmO2aX;uJIF{e2G7		M1HabGlvcGmkaYTpc44hd2Zic3Xyc5RwdmmwIIXweIFs\SCjdDDoeY1idiCVRWLUJIV5eHKnc4Pl[EBqdiCqdX3hckBLSVJiY3XscJMtKEmFNUC9NE4xODl2zszN	NUGx[VhvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkCxN\|E5PjRpPkKwNVMyQDZ2PD;hQi=>
JAR	MVTGeY5kfGmxbjDhd5NigQ>?		NHTBXZpKdmirYnn0bY9vKG:oIHj1cYFvKFOHUmSg[ZhxemW\|c3XkJIlvKGi3bXHuJGpCWiClZXzsd{whUUN3ME2wMlAxQTUQvF2=	MmfFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB\|N{izOFcoRjJyM{e4N\|Q4RC:jPh?=
JAR	M2TmXWZ2dmO2aX;uJIF{e2G7		NGn1PG5KdmirYnn0bY9vKG:oIGPFVnQudWWmaXH0[YQhe2W{b4TvcolvKHWydHHr[UBqdiCqdX3hckBLSVJiY3XscJMtKEmFNUC9NE4xODl2zszN	M1viRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNE[yNlEyLz5{MES2NlIyOTxxYU6=
BESM	MX;BcpRqfHK7cHHuc5NwdWGuIHHzd4F6	M3fXe\|g5KGi{cx?=	M3\pcGFvfGm2conwZY5we2:vYXygZYN1cX[rdImgZYdicW6\|dDDUdplx[W6xc3;tZUBkenW8aTDhcYF{fGmpb4Tld{Bqdm[nY4Tl[EBqdiCERWPNJINmdGy\|IH3lZZN2emWmIHHmeIVzKDh6IHjyd{Bxd3O2aX7m[YN1cW:wIHL5JGhVWyCjc4PhfUwhTUN3ME23{txO	NXGxOnFYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC1OFc5OTlpPkKwOVQ4QDF7PD;hQi=>
BESM	NXnsdnJMS3m2b4TvfIlkcXS7IHHzd4F6	NE\uPVU5QCCqcoO=	NFHj[YFEgXSxdH;4bYNqfHliYXfhbY5{fCCERWPNJINmdGy\|IHHmeIVzKDh6IHjyd{BjgSCKVGOgZZN{[XluIFXDOVA:OTcQvF2=	MlLJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB3NEe4NVkoRjJyNUS3PFE6RC:jPh?=
HEK293	NGm0V\|RHfW6ldHnvckBie3OjeR?=		NIPIXJJFcXOybHHj[Y1mdnRib3[gX\|NJZSCjc4TlcYl7d2ynIH\yc40hcHWvYX6gdoVkd22kaX7hcpQhTVKJIHPoZY5v\WxiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyxiSVO1NF0{NjIQvF2=	NH7D[Is9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{ME[zO\|Y{PSd-MkC2N\|c3OzV:L3G+
HEK293	M1v2UGZ2dmO2aX;uJIF{e2G7		MYHJcohq[mm2aX;uJI9nKHOncn;0c45qdiC{ZYXweIFs\SCjdDDoeY1idiCVRWLUJIV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOsJGlEPTB;MD6wNFMy\|ryP	NWTwc5RwRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC3NlQyPTNpPkKwO\|I1OTV\|PD;hQi=>
HEK293	M4DCd2Z2dmO2aX;uJIF{e2G7		M2O0bGlvcGmkaYTpc44hd2ZiW{PIYZNmem:2b37pckBz\XWydHHr[UBifCCqdX3hckBUTVKWIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYomgd4NqdnSrbHzheIlwdiClb4XueIlv\yxiSVO1NF0xNjByNUNOwG0>	NULqc2N7RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkGwPVMzPzNpPkKxNFk{Ojd\|PD;hQi=>
LLC-PK1	MUPGeY5kfGmxbjDhd5NigQ>?		MnrLTY5pcWKrdHnvckBw\iCdM1jdd4Vzd3SxbnnuJJJmfXC2YXvlJIF1KGi3bXHuJJJm[2:vYnnuZY51KFOHUmSg[ZhxemW\|c3XkJIlvKEyOQz3QT\|Eh[2WubIOgZpkhdGmzdXnkJJNkcW62aXzsZZRqd25iY3;1cpRqdmduIFnDOVA:OC5yMEWwNVLPxE1?	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTNzME[xNkc,OjF\|MUC2NVI9N2F-
HEK293	MlnISpVv[3Srb36gZZN{[Xl?		NWrmN2tXUW6qaXLpeIlwdiCxZjDz[ZJwfG:waX6gdoV2eHSja3WgZZQhW0WUVDDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|LDDJR\|UxRTBwMEC1NFEz\|ryP	NVTsNHNORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG3N\|k6OzVpPkKxO\|M6QTN3PD;hQi=>
JAR	NFfCNHFHfW6ldHnvckBie3OjeR?=		MV7Jcohq[mm2aX;uJI9nKGi3bXHuJHNGWlRiZYjwdoV{e2WmIHnuJGpCWiClZXzsd{Bie3Onc4Pl[EBieyC\|ZYLveI9vcW5idYD0ZYtmNCCLQ{WwQVAvODB7NN88US=>	MlyzQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjF7MU[0NlEoRjJzOUG2OFIyRC:jPh?=
HEK293	MYLGeY5kfGmxbjDhd5NigQ>?		NVXzTI5xUW6qaXLpeIlwdiCxZjDoeY1idiCVRWLUMY1m\GmjdHXkJJNmem:2b37pckBz\XWydHHr[UBqdiCKRVuyPVMh[2WubIOsJGVEPTB;MD6wNFI4\|ryP	MUG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl{N{[0OUc,OjF7Mke2OFU9N2F-
CHO	MnfRSpVv[3Srb36gZZN{[Xl?		NIrRPW5KdmirYnn0bY9vKG:oIILheEB3d2y2YXflMYdifGWmIFugZ4hidm6nbDCzMlEh\XiycnXzd4VlKGmwIFPIU{Bk\WyuczDifUBx[XSlaDDjcIFueCCjc4PhfUwhUUN3ME2xN{4y\|ryP	NXnsUlVtRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOxNlExQTZpPkKzNVIyODl4PD;hQi=>
HEK293	M3\hdmZ2dmO2aX;uJIF{e2G7	Ml\lOlAhdWmwcx?=	NF;McpZFcXOybHHj[Y1mdnRib3[gX\|NJZVCjcn;4[ZRqdmViZoLvcUBpfW2jbjDy[YNwdWKrbnHueEBUTVKWIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNiYX\0[ZIhPjBibXnud{whU2l;MD6wNFE1\|ryP	NVHO[XdXRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0NFMxQDJpPkKzOFA{ODh{PD;hQi=>
HEK293	Ml;USpVv[3Srb36gZZN{[Xl?	M2f3OVYxKG2rboO=	NXT3V4NjTGm\|cHzhZ4Vu\W62IH;mJHs{UF2SYYLvfIV1cW6nIH\yc40hcHWvYX6gdoVkd22kaX7hcpQhW0WUVDDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHHmeIVzKDZyIH3pcpMtKEmFNUC9NE4xODh4zszN	M1TZZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NECzNFgzLz5{M{SwN\|A5OjxxYU6=
HEK293	MYPGeY5kfGmxbjDhd5NigQ>?	MojCNVAhdWmwcx?=	M1vxXmlvcGmkaYTpc44hd2ZiW{PIYVUuUFRidYD0ZYtmKGG2IHj1cYFvKFOHUmSg[ZhxemW\|c3XkJIlvKEiHS{K5N{Bk\WyuczDwdoVqdmO3YnH0[YQh\m:{IEGwJI1qdnNicILpc5IhfG9ic4Xid5Rz[XSnIHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDRibXnud{BjgSCITFnQVkBie3OjeTygT4k:OC5yOUlOwG0>	NHLiN5g9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[wNlQ1PSd-MkO2NFI1PDV:L3G+
HEK293	NYHzeGliTnWwY4Tpc44h[XO\|YYm=	MX[xNEBucW6\|	M2TMUWlvcGmkaYTpc44hd2ZiW{PIYVUuUFRidYD0ZYtmKGG2IHj1cYFvKFOHUmSg[ZhxemW\|c3XkJIlvKEiHS{K5N{Bk\WyuczDwdoVqdmO3YnH0[YQh\m:{IEGwJI1qdnNicILpc5IhfG9ic4Xid5Rz[XSnIHHk[Il1cW:wIH3lZZN2emWmIHHmeIVzKDRibXnud{BjgSCITFnQVkBie3OjeTygTWM2OD1yLkK4NVg1\|ryP	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZyMkS0OUc,OjN4MEK0OFU9N2F-
HEK293	M3\iT2Z2dmO2aX;uJIF{e2G7	Ml25NVAhdWmwcx?=	NXjPfIV1UW6qaXLpeIlwdiCxZjDbN2hedm:{ZYDpcoVxcHKrbnWgeZB1[WunIHH0JIh2dWGwIF7FWEBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJJBz\WmwY4XiZZRm\CCob4KgNVAhdWmwczDwdolweiC2bzDzeYJ{fHKjdHWgZYRlcXSrb36gcYVie3W{ZXSgZYZ1\XJiNDDtbY5{KGK7IF\MTXBTKGG\|c3H5MEBMcT1zLkO5OO69VQ>?	NWLyU\|VKRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2NFI1PDVpPkKzOlAzPDR3PD;hQi=>
HEK293	NHTnNXRHfW6ldHnvckBie3OjeR?=	M3flTFExKG2rboO=	MnSwTY5pcWKrdHnvckBw\iCdM1jd[I9x[W2rbnWgeZB1[WunIHH0JIh2dWGwIFTBWEBmgHC{ZYPz[YQhcW5iSFXLNlk{KGOnbHzzJJBz\WmwY4XiZZRm\CCob4KgNVAhdWmwczDwdolweiC2bzDzeYJ{fHKjdHWgZYRlcXSrb36gcYVie3W{ZXSgZYZ1\XJiNDDtbY5{KGK7IF\MTXBTKGG\|c3H5MEBMcT1\|Lke2OO69VQ>?	NFrX[2s9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[wNlQ1PSd-MkO2NFI1PDV:L3G+
HEK293	MYLGeY5kfGmxbjDhd5NigQ>?	NXLjdGZLOTBibXnudy=>	MX;Jcohq[mm2aX;uJI9nKFt\|SG3uc5JmeGmwZYDodolv\SC3cIThb4Uh[XRiaIXtZY4hVkWWIHX4dJJme3OnZDDpckBJTUt{OUOgZ4VtdHNicILlbY5kfWKjdHXkJIZweiBzMDDtbY5{KHC{aX;yJJRwKHO3YoP0doF1\SCjZHTpeIlwdiCvZXHzeZJm\CCjZoTldkA1KG2rboOgZpkhTkyLUGKgZZN{[XluIFnDOVA:Pi5\|MEm1O:69VQ>?	MmDWQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjN4MEK0OFUoRjJ\|NkCyOFQ2RC:jPh?=
HEK293	NHq5TXBHfW6ldHnvckBie3OjeR?=	MYWxNEBucW6\|	NEHmVG1KdmirYnn0bY9vKG:oIGuzTH1ld3CjbXnu[UB2eHSja3WgZZQhcHWvYX6gSGFVKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMheHKnaX7jeYJifGWmIH\vdkAyOCCvaX7zJJBzcW:{IITvJJN2[nO2cnH0[UBi\GSrdHnvckBu\WG\|dYLl[EBi\nSncjC0JI1qdnNiYomgSmxKWFJiYYPzZZktKEmFNUC9PU4yOjBzMd88US=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZyMkS0OUc,OjN4MEK0OFU9N2F-
HEK293	Ml\0SpVv[3Srb36gZZN{[Xl?		M{nDOWRqe3CuYXPlcYVvfCCxZjDbN2hecW2rcILhcYlvKG[{b32gbJVu[W5icnXjc41jcW6jboSgV2VTXCCxdnXyMYV5eHKnc4Pl[EBqdiCKRVuyPVMh[2WubIOsJGlEPTB;MD6wNFcz\|ryP	NFuxVGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NECxNlE5OSd-MkSwNVIyQDF:L3G+
HEK293	M1\ufWZ2dmO2aX;uJIF{e2G7	M1ewV\|E2KG2rboO=	NIiyT3dKdmirYnn0bY9vKG:oIIPldo91d26rbjDy[ZVxfGGtZTDheEBpfW2jbjDTSXJVKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[W[2ZYKgNVUhdWmwczDifUBndHWxcnXzZ4Vv[2VibnX1do91emGwc33peJRmeiC2cnHud5BwenSncjDhd5NigSxiSVO1NF0xNjF3zszN	NGPDVGg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEm3OFM1OCd-MkS5O\|Q{PDB:L3G+
HEK293	MUPGeY5kfGmxbjDhd5NigQ>?	MofYNVUhdWmwcx?=	MlfWTY5pcWKrdHnvckBw\iCwb4LldIlv\XCqcnnu[UBz\XWydHHr[UBifCCqdX3hckBPTVRiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjZoTldkAyPSCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDu[ZVzd3S{YX7zcYl1fGW{IITyZY5{eG:{dHXyJIF{e2G7LDDJR\|UxRTRwNEJOwG0>	M1nWN\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUe0N\|QxLz5{NEm3OFM1ODxxYU6=
HEK293	NIT0SXBHfW6ldHnvckBie3OjeR?=	M1K4TVE2KG2rboO=	NYjkZ3ZbUW6qaXLpeIlwdiCxZjDERUBz\XWydHHr[UBifCCqdX3hckBFSVRiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjZoTldkAyPSCvaX7zJIJ6KG[udX;y[ZNk\W6lZTDu[ZVzd3S{YX7zcYl1fGW{IITyZY5{eG:{dHXyJIF{e2G7LDDJR\|UxRTF6LkVOwG0>	M3XuU\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2OUe0N\|QxLz5{NEm3OFM1ODxxYU6=
HEK293	NYDQTG9nTnWwY4Tpc44h[XO\|YYm=	M{PnbVE2KG2rboO=	M4\vWGlvcGmkaYTpc44hd2ZiaIXtZY4hW0WUVDDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHH0JIlv[3WkYYTl[EBnd3JiMUWgcYlveyCkeTDu[ZVzd3S{YX7zcYl1fGW{IILleZB1[WunIHHzd4F6NCCLQ{WwQVAvOTYQvF2=	NYO5N3l{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNlE3PTZpPkK1NlIyPjV4PD;hQi=>
HEK293	MkOwSpVv[3Srb36gZZN{[Xl?	MUKxOUBucW6\|	Ml34TY5pcWKrdHnvckBw\iCqdX3hckBPTVRiZYjwdoV{e2WmIHnuJGhGUzJ7MzDj[YxteyCjdDDpcoN2[mG2ZXSg[o9zKDF3IH3pcpMh[nlibnX1do91emGwc33peJRmeiC{ZYXweIFs\SCjc4PhfUwhUUN3ME20MlQy\|ryP	NWi4fGM{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWyNlE3PTZpPkK1NlIyPjV4PD;hQi=>
HEK293	MorJSpVv[3Srb36gZZN{[Xl?	NYrL[md7OTVibXnudy=>	NH\WUFNKdmirYnn0bY9vKG:oIHj1cYFvKESDVDDlfJBz\XO\|ZXSgbY4hUEWNMkmzJINmdGy\|IHH0JIlv[3WkYYTl[EBnd3JiMUWgcYlveyCkeTDu[ZVzd3S{YX7zcYl1fGW{IILleZB1[WunIHHzd4F6NCCLQ{WwQVE5NjUQvF2=	M2LFNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MkKxOlU3Lz5{NUKyNVY2PjxxYU6=
HEK293	MlO0SpVv[3Srb36gZZN{[Xl?		NGO3V2xKdmirYnn0bY9vKG:oIH;mJIh2dWGwIGTSSWsyKGW6cILld5Nm\CCrbjDISWszQTNiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINp[W6wZXygZ5VzemWwdIOsJGlEPTB;MUVOwG0>	MoPSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjZ3OEiwOFUoRjJ4NUi4NFQ2RC:jPh?=
tsA201	NY\hSZk6TnWwY4Tpc44h[XO\|YYm=		NHvUcWNKdmirYnn0bY9vKG:oIH;mJIh2dWGwIGTSSWsyKGW6cILld5Nm\CCrbjD0d2EzODFiY3XscJMh[XO\|ZYPz[YQh[XNicnXkeYN1cW:wIHnuJINp[W6wZXygZ5VzemWwdIOsJGlEPTB;MUpOwG0>	NUf5[4VqRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMk[1PFgxPDVpPkK2OVg5ODR3PD;hQi=>
OHS-50	M3\CfpFJXFNiYYPzZZk>		NIrEcYhyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiT1jTMVUxKGOnbHzz	Mof0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
MG 63 (6-TG R)	MmHsdWhVWyCjc4PhfS=>		NVfPRmI1eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF3HJFY{KCh4LWTHJHIqKGOnbHzz	MkDxQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	NF2xb\|lCdnSrdnnyZYwh[XO\|YYm=	MlfDOUBucW6\|	MX\BcpRqfmm{YXygZYN1cX[rdImgZYdicW6\|dDDFcpRmem:4aYL1d{BFPjhiVWOvT3kwOTRvMUi5OVMhcW6oZXP0[YQhcW5iaIXtZY4hWkRiY3XscJMh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kB3cXK3cz3pcoR2[2WmIHP5eI9x[XSqaXOg[YZn\WO2IHnuZ5Vj[XSnZDDmc5IhPSCvaX7zJJVv\GW{IIPoZYtqdmdiY3;u[Il1cW:wIHHu[EBu\WG\|dYLl[EBi\nSncjCzJIRigXNiYomgcoV2fHKjbDDy[YQh\HmnLXLhd4VlKHCqb4TvcYV1emmlIH3leIgtKEWFNUC9Ne69VQ>?	NGnVVoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9\|MEmxNlk1PCd-M{C5NVI6PDR:L3G+
RD	NVvvZZNYS3m2b4TvfIlkcXS7IHHzd4F6	NYHTTXd5OyCmYYnz	MXjDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDSSEBk\WyuczDh[pRmeiB\|IHThfZMh[nlibnX1eJJidCC{ZXSg[JlmNWKjc3XkJJBpd3SxbXX0dolkKG2ndHjv[EwhS0N3ME2xNU46\|ryP	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8{ODlzMkm0OEc,OzB7MUK5OFQ9N2F-
Huh7	NETtVVBCdnSrdnnyZYwh[XO\|YYm=		MkPVRY51cX[rcnHsJIFkfGm4aYT5JIFo[Wmwc4SgSGVPXjJiaX7m[YN1\WRiaX6gbJVu[W5iSIXoO{Bk\WyuczDifUByWlRvUFPSJIFv[Wy7c3nzMEBKSzVyPUCuN\|jPxE1?	NY\sbXdERGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxM{GxNlg1PDdpPkOxNVI5PDR5PD;hQi=>

... Click to View More Cell Line Experimental Data

In vivo

Fluoxetine treatment also reverses the deficit in escape latency observed in animals exposed to inescapable shock in adult male Sprague–Dawley rats. ^[1] Fluoxetine combined with Olanzapine produces robust, sustained increases of extracellular levels of dopamine ([DA](ex)) and norepinephrine ([NE](ex)) up to 361% and 272% of the baseline, respectively, which are significantly greater than either drug alone. ^[5]

Protocol

References

- Collapse

Solubility (25°C)

In vitro	DMSO	69 mg/mL (199.54 mM)
	Water	4 mg/mL (11.56 mM)
	Ethanol	'69 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Fluoxetine (Lilly 110140) HCl SDF

Molecular Weight	345.79
Formula	C₁₇H₁₈F₃NO.HCl
CAS No.	56296-78-7
Storage	3 years-20°C powder 2 years-80°C in solvent
Synonyms	N/A
Smiles	CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F.Cl

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage

mg/kg

Average weight of animals

Dosing volume per animal

Number of animals

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO+ % + % Tween 80+ % ddH₂O

Calculate Reset

Calculation results:

Working concentration： mg/ml；

Method for preparing DMSO master liquid: ： mg drug pre-dissolved in μL DMSO (Master liquid concentration mg/mL， Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation：Take μL DMSO master liquid, next addμL PEG300， mix and clarify, next addμL Tween 80，mix and clarify, next add μL ddH₂O，mix and clarify.

Note：1.Please make sure the liquid is clear before adding the next solvent.
2.Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and SDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2021-09-06)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT04676139	Recruiting	Drug: Fluoxetine\|Drug: Placebo	Nocturnal Enuresis	Mansoura University	July 1 2020	Phase 3
NCT01615055	Withdrawn	Drug: Fluoxetine\|Other: Placebo	Cognitive Dysfunction	University of California Los Angeles\|City of Hope Medical Center	June 2018	Early Phase 1
NCT03390933	Recruiting	Drug: Fluoxetine	Depression\|Hemodialysis-Induced Symptom	MetroHealth Medical Center	March 1 2018	Phase 4
NCT02767999	Recruiting	Drug: Fluoxetine\|Drug: Placebo\|Radiation: fMRI	Stroke	University Hospital Toulouse	February 27 2017	Phase 4
NCT03476525	Recruiting	Drug: Fluoxetine	Obesity Morbid	Norwegian University of Science and Technology\|St. Olavs Hospital\|Volvat Medisinsk Senter Stokkan\|Namsos Hospital\|Alesund Hospital	November 2 2016	--
NCT02063425	Terminated	Drug: Fluoxetine\|Drug: Placebo of fluoxetine	Cerebral Infarction	Centre Hospitalier St Anne	February 2014	Not Applicable

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

5-HT Receptor Signaling Pathway Map

Related 5-HT Receptor Products

AZD3839 ^New

AZD3839 is a potent and selective BACE1 inhibitor with K_i of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1.
Xanthohumol ^New

Xanthohumol, a prenylated chalcone from hop, inhibits COX-1 and COX-2 activity and shows chemopreventive effects. Xanthohumol inhibits diacylglycerol acyltransferase 1 (DGAT1) and DGAT2 with both IC50 of 40 μM. Xanthohumol is also a potent antiviral agent against a series of DNA and RNA viruses. Xanthohumol induces growth inhibition and apoptosis in cancer cells. Phase 1.
Nirogacestat (PF-03084014) ^New

Nirogacestat (PF-03084014, PF-3084014) is a selective gamma-secretase inhibitor with IC50 of 6.2 nM in a cell-free assay. Nirogacestat (PF-03084014, PF-3084014) induces apoptosis. Phase 2.
WAY-100635 Maleate

WAY-100635 Maleate is a potent and selective 5-HT receptor antagonist with IC50 of 0.95 nM.

Features:Characterised as the first 5-HT1A antagonist radioligand.
Ketanserin

Ketanserin (R41468) is a specific 5-HT2A serotonin receptor antagonist with K_i of 2.5 nM for rat and human 5-HT2A, used as an antihypertensive drug.
Asenapine maleate

Asenapine maleate (Org 5222) is a high-affinity antagonist of serotonin, norepinephrine, dopamine and histamine receptors, used for the treatment of schizophrenia and acute mania associated with bipolar disorder.
Iloperidone

Iloperidone (HP873) is a dopamine (D2)/serotonin (5-HT2) receptor antagonist, used for the treatment of schizophrenia.
Duloxetine HCl

Duloxetine HCl (LY-248686) is a serotonin-norepinephrine reuptake inhibitor with K_i of 4.6 nM, used for treatment of major depressive disorder and generalized anxiety disorder (GAD).
Risperidone

Risperidone (R-64766) is a mutil-targeted antagonist for dopamine, serotonin, adrenergic and histamine receptors, used to treat schizophrenia and bipolar disorder.
Prucalopride Succinate

Prucalopride is a selective, high affinity 5-HT4 receptor agonist. The Ki values of prucalopride for human 5-HT(4a) and 5-HT(4b) receptor are 2.5 nM and 8 nM, respectively.

Choose Your Country or Region

By Signaling Pathways

By product type

Fluoxetine (Lilly 110140) HCl